Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
Marinomed Biotech AG: Court opens restructuring proceedings without self-administration
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
Lucia Ziegler, MSc
Head of Investor & Public Relations